RejuvenAir
rejuvenair.com
Health & Medical Electronics
Higher Education
As featured in
Claim pageClaim
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Horizon Technology Finance, TVM Capital Life Science
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Horizon Technology Finance 
TVM Capital Life Science Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
First purpose-built, minimally invasive, ultrasound-based system designed to treat patients with pulmonary hypertension due to left-sided…
Qufora is a medical device company that works to enable people with chronic bowel disorders to live a better life. Your life Our…
Innovative medical device to treat chronic wounds. DISCOVER.
SWI has been developing less invasive sounds therapy device using low-intensity pulsed ultrasound (LIPUS) and shockwave ablation catheter…
LIVSMED is a global medical device company. We contribute to life extension of mankind by creating innovative laparoscopic instruments to…
Audion Therapeutics is a clinical-stage company dedicated to the development of therapies to treat Hearing Loss About Audion Hearing Loss…
News
Pivotal SPRAY-CB Trial of RejuvenAir Published in American Journal of Respiratory and Critical Care Medicine Newswise
CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today announced the publication in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) of results from SPRAY-CB (NCT03893370), the pivotal rando
Read more
Report
Pivotal SPRAY-CB Trial of RejuvenAir Published in American Journal of Respiratory and Critical Care Medicine
/PRNewswire/ -- CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today announced the publication in the American...
Read more
Report
CSA Medical Submits PMA for RejuvenAir System Following Positive Results from Pivotal SPRAY-CB Trial
SPRAY-CB met its primary endpoint and multiple secondary endpoints with statistical significance, FDA review underway BOSTON, Jan. 7, 2026 /PRNewswire/ - CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today anno
Read more
Report
CSA Medical Submits PMA for RejuvenAir System Following Positive Results from Pivotal SPRAY-CB Trial
CSA Medical, Inc., a medical device company focused on interventional pulmonary therapies, today announced the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RejuvenAir System for the treatment
Read more
Report
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir System
Underlying proof of rejuvenative healing indicative of airway remodeling corresponds with clinical efficacy and improved quality of life Boston, MA-Oct 8, 2024: /PRNewswire/ - CSA Medical, Inc., a leader in developing spray cryotherapy solutions for the t
Read more
Report
CSA Medical Announces New Scientific Data Utilizing Metered Cryospray with the RejuvenAir System for the Treatment of Chronic Bronchitis
Research reveals rejuvenative changes in cellular populations indicative of airway remodeling correspond with clinical efficacy and improved quality of life BOSTON, Sept. 16, 2024 /PRNewswire/ -CSA Medical, Inc., today announced multiple presentations at
Read more
Report
CSA Medical: $53 Million (Series D) Raised For Advancing RejuvenAir System
CSA Medical, the developer of The RejuvenAir System (a Breakthrough Medical Device advancing the power of liquid nitrogen spray cryotherapy for the treatment of chronic bronchitis), announced the completion of an oversubscribed $53 million Series D prefer
Read more
Report
CSA Medical Raises $53 Million in Series D Financing to Support PMA of the RejuvenAir System
CSA Medical Inc. today announced the completion of an oversubscribed $53 million Series D preferred stock equity financing.
Read more
Report
CSA Medical Announces 500th Metered CryoSpray Procedure for the Treatment of Chronic Bronchitis
The RejuvenAir System is a minimally invasive medical device therapy which aims to target the underlying cause of COPD with Chronic Bronchitis BOSTON, Feb. 7, 2024 /PRNewswire/ - CSA Medical Inc., a developer of medical devices advancing the power of liqu
Read more
Report
First Randomized Controlled Study with RejuvenAir for Chronic Bronchitis shows Clinically Significant Results
Metered Cryospray treats damaged airways enabling a rejuvenative healing response BOSTON, Sept. 6, 2022 /PRNewswire/ - CSA Medical, Inc., today announced results from the first randomized, controlled study of Metered Cryospray (MCS) utilizing the RejuvenA
Read more
Report
Show more news